SCHEMBL29907503

SCHEMBL29907503

CC(C)(O)c1cc(C(=O)Nc2ccc(OC(F)F)cc2)c(=O)n(-c2ccccc2OCC(F)(F)F)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 6/20 0.60
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
THRB P10828 2/20 0.41
NPSR1 Q6W5P4 2/20 0.40
TP53 P04637 2/20 0.40
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
PAX8 Q06710 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SCN8A Q9UQD0 2/20 0.38
SCN10A Q9Y5Y9 2/20 0.38
ALDH1A1 P00352 1/20 0.38
S1PR1 P21453 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907490 0.89 UGCG (0.75) UGCGMAPTSMN1; SMN2THRBTP53
SCHEMBL29601498 0.88 UGCG (0.55) UGCGMAPTSMN1; SMN2THRBNPSR1
SCHEMBL29907396 0.87 UGCG (0.54) UGCGMAPTSMN1; SMN2THRBNPSR1
SCHEMBL29907628 0.86 UGCG (0.61) UGCGMAPTSMN1; SMN2THRBTP53
SCHEMBL29907406 0.85 UGCG (0.52) UGCGMAPTSMN1; SMN2NPSR1KDM4E
SCHEMBL29907436 0.85 UGCG (0.64) UGCGMAPTSMN1; SMN2THRBTP53
SCHEMBL29907407 0.81 UGCG (0.61) UGCGMAPTSMN1; SMN2THRBLMNA
SCHEMBL29907410 0.81 UGCG (0.75) UGCGMAPTSMN1; SMN2THRB
SCHEMBL29907497 0.76 UGCG (0.81) UGCGKDM4ESCN8ASCN10A
SCHEMBL29907426 0.75 UGCG (1.00) UGCGMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC UGCG 10/4885MAPT 772/4885SMN1; SMN2 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.